Stay updated on SIIT + Pembrolizumab in Follicular Lymphoma Clinical Trial
Sign up to get notified when there's something new on the SIIT + Pembrolizumab in Follicular Lymphoma Clinical Trial page.

Latest updates to the SIIT + Pembrolizumab in Follicular Lymphoma Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedThe page now presents a 403 Forbidden error with a simple header and a Home option. This indicates the study record is inaccessible and the detailed content is no longer displayed.SummaryDifference20%

- Check20 days agoNo Change Detected
- Check34 days agoChange DetectedRevision label updated from v3.6.5 to v3.6.6, signaling a small site release without changes to study information.SummaryDifference0.1%

- Check55 days agoChange DetectedRevision tag updated from v3.6.4 to v3.6.5. This indicates a minor software update and does not modify the study details or visible content.SummaryDifference0.1%

- Check70 days agoChange DetectedThe page revision updated from v3.6.3 to v3.6.4, representing a minor version update to the page rather than a substantive content change.SummaryDifference0.1%

- Check91 days agoChange DetectedThe page's revision marker was updated from v3.6.2 to v3.6.3, indicating a minor update to the page version.SummaryDifference0.1%

- Check99 days agoChange DetectedThe revision indicator on the page updates to v3.6.2, replacing the previous v3.6.0.SummaryDifference0.1%

Stay in the know with updates to SIIT + Pembrolizumab in Follicular Lymphoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the SIIT + Pembrolizumab in Follicular Lymphoma Clinical Trial page.